These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 17587564

  • 1. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK).
    Aballéa S, Boler A, Craig A, Wasan H.
    Eur J Cancer; 2007 Jul; 43(11):1687-93. PubMed ID: 17587564
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.
    Cancer; 2007 Mar 15; 109(6):1082-9. PubMed ID: 17265519
    [Abstract] [Full Text] [Related]

  • 3. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.
    Health Technol Assess; 2006 Nov 15; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [Abstract] [Full Text] [Related]

  • 4. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
    Koperna T, Semmler D.
    Hepatogastroenterology; 2003 Nov 15; 50(54):1903-9. PubMed ID: 14696430
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T, Takeuchi T, Fukuda T, Shimozuma K, Ohashi Y.
    Value Health; 2012 Nov 15; 15(2):255-60. PubMed ID: 22433756
    [Abstract] [Full Text] [Related]

  • 6. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N.
    Cancer; 2012 Jun 15; 118(12):3173-81. PubMed ID: 22020739
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.
    Uyl-de Groot CA, Vermorken JB, Hanna MG, Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM.
    Vaccine; 2005 Mar 18; 23(17-18):2379-87. PubMed ID: 15755632
    [Abstract] [Full Text] [Related]

  • 8. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group.
    Acta Oncol; 2009 Mar 18; 48(3):368-76. PubMed ID: 19242829
    [Abstract] [Full Text] [Related]

  • 9. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A.
    J Clin Oncol; 2007 Aug 20; 25(24):3732-8. PubMed ID: 17704423
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant therapy of colon cancer: current status and future directions.
    Chung KY, Saltz LB.
    Cancer J; 2007 Aug 20; 13(3):192-7. PubMed ID: 17620769
    [Abstract] [Full Text] [Related]

  • 11. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, André T, Haller DG, Sargent DJ.
    J Clin Oncol; 2008 May 10; 26(14):2336-41. PubMed ID: 18467725
    [Abstract] [Full Text] [Related]

  • 12. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ.
    J Clin Oncol; 2007 Aug 10; 25(23):3456-61. PubMed ID: 17687149
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q.
    World J Gastroenterol; 2014 Dec 21; 20(47):17976-84. PubMed ID: 25548497
    [Abstract] [Full Text] [Related]

  • 14. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group.
    Br J Cancer; 2007 Oct 22; 97(8):1021-7. PubMed ID: 17895886
    [Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer.
    Lairson DR, Parikh RC, Cormier JN, Chan W, Du XL.
    Pharmacoeconomics; 2014 Oct 22; 32(10):1005-13. PubMed ID: 24920195
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant chemotherapy for colon cancer: evidence on improvement in survival.
    Samantas E, Dervenis C, Rigatos SK.
    Dig Dis; 2007 Oct 22; 25(1):67-75. PubMed ID: 17384510
    [Abstract] [Full Text] [Related]

  • 17. Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer.
    Gibbs P, Handolias D, McLaughlin S, Chapman M, Johns J, Faragher I.
    Intern Med J; 2008 Apr 22; 38(4):265-9. PubMed ID: 18298558
    [Abstract] [Full Text] [Related]

  • 18. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
    Lerdkiattikorn P, Chaikledkaew U, Lausoontornsiri W, Chindavijak S, Khuhaprema T, Tantai N, Teerawattananon Y.
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr 22; 15(4):687-700. PubMed ID: 25327502
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
    Monz BU, König HH, Leidl R, Staib L, Link KH.
    Pharmacoeconomics; 2003 Apr 22; 21(10):709-19. PubMed ID: 12828493
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.
    Fields AL, Keller A, Schwartzberg L, Bernard S, Kardinal C, Cohen A, Schulz J, Eisenberg P, Forster J, Wissel P.
    J Clin Oncol; 2009 Apr 20; 27(12):1941-7. PubMed ID: 19273708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.